Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
出版年份 2020 全文链接
标题
Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
作者
关键词
-
出版物
TUMORI
Volume -, Issue -, Pages 030089162094502
出版商
SAGE Publications
发表日期
2020-07-30
DOI
10.1177/0300891620945029
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells
- (2018) Zili Zhang et al. Autophagy
- Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults
- (2017) Jia-Guo Zhao et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials
- (2017) Jun Li et al. Oncotarget
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial
- (2015) Katrin Hoffmann et al. BMC CANCER
- Erratum to: “EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma” [J Hepatol 2012;56:908–943]
- (2015) et al. JOURNAL OF HEPATOLOGY
- TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial
- (2014) Andreas Erhardt et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib
- (2013) Yan-Ru Deng et al. JOURNAL OF AUTOIMMUNITY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial
- (2012) Young-Hwa Chung et al. INTERNATIONAL JOURNAL OF CANCER
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
- (2012) D. Sansonno et al. ONCOLOGIST
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
- (2011) Timothy M. Pawlik et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma
- (2010) Yu-Yun SHAO et al. Asia-Pacific Journal of Clinical Oncology
- New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
- (2010) Yan Wang et al. JOURNAL OF HEPATOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Hepatocellular carcinoma in the Asia pacific region
- (2009) Man-Fung Yuen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements
- (2009) JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started